Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis

American Journal of Medicine

Volumn 126, Issue 12, 2013, Pages 1089-1098

  Greenberg, Jeffrey D ^a   Spruill, Tanya M ^b   Shan, Ying ^c   Reed, George ^c   Kremer, Joel M ^d   Potter, Jeffrey ^a   Yazici, Yusuf ^a   Ogedegbe, Gbenga ^b   Harrold, Leslie R ^c  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Disease activity; Disparities; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; REMISSION; RHEUMATOID ARTHRITIS;

DISEASE ACTIVITY; DISPARITIES; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HEALTH STATUS DISPARITIES; HUMANS; ODDS RATIO; RISK FACTORS; UNITED STATES;

EID: 84888086202     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.09.002     Document Type: Article

References (26)

1. S.E. Gabriel The epidemiology of rheumatoid arthritis Rheum Dis Clin North Am 27 2001 269 281
2. F. Wolfe, K. Michaud, O. Gefeller, and H.K. Choi Predicting mortality in patients with rheumatoid arthritis Arthritis Rheum 48 2003 1530 1542
3. H. Birnbaum, C. Pike, R. Kaufman, M. Marynchenko, Y. Kidolezi, and M. Cifaldi Societal cost of rheumatoid arthritis patients in the US Curr Med Res Opin 26 2010 77 90
4. K.G. Saag, G.G. Teng, and N.M. Patkar American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
5. J.A. Singh, D.E. Furst, and A. Bharat 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 64 2012 625 639
6. J.S. Smolen, R. Landewe, and F.C. Breedveld EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Ann Rheum Dis 69 2010 964 975
7. J.S. Smolen, D. Aletaha, and J.W. Bijlsma Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis 69 2010 631 637
8. Y. Yazici, H. Kautiainen, and T. Sokka Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data J Rheumatol 34 2007 311 315
9. B. Bruce, J.F. Fries, and K.N. Murtagh Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study J Rheumatol 34 2007 1475 1479
10. J.L. Barton, L. Trupin, and D. Schillinger Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics Arthritis Care Res (Hoboken) 63 2011 1238 1246
11. U.T. Iren, M.S. Walker, E. Hochman, and R. Brasington A pilot study to determine whether disability and disease activity are different in African-American and Caucasian patients with rheumatoid arthritis in St. Louis, Missouri, USA J Rheumatol 32 2005 602 608
12. E. Zerhouni Medicine. The NIH Roadmap Science 302 2003 63 72
13. J. Kremer The CORRONA database Ann Rheum Dis 64 Suppl 4 2005 iv37 iv41
14. J.M. Kremer The CORRONA database Autoimmun Rev 5 2006 46 54
15. D. Aletaha, V.P. Nell, and T. Stamm Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score Arthritis Res Ther 7 2005 R796 R806
16. D. Aletaha, and J. Smolen The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis Clin Exp Rheumatol 23 5 Suppl 39 2005 S100 S108
17. L.F. Callahan, T. Pincus, J.W. Huston 3rd, R.H. Brooks, E.P. Nance Jr., and J.J. Kaye Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years Arthritis Care Res 10 1997 381 394
18. S.E. Geller, M.G. Adams, and M. Carnes Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials J Womens Health (Larchmt) 15 2006 1123 1131
19. G.W. Cannon, T.R. Mikuls, and C.L. Hayden Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice Arthritis Care Res (Hoboken) 63 2011 1680 1690
20. F. Constantinescu, S. Goucher, A. Weinstein, and L. Fraenkel Racial disparities in treatment preferences for rheumatoid arthritis Med Care 47 2009 350 355
21. F. Constantinescu, S. Goucher, A. Weinstein, W. Smith, and L. Fraenkel Understanding why rheumatoid arthritis patient treatment preferences differ by race Arthritis Rheum 61 2009 413 418
22. F. Kurreeman, K. Liao, and L. Chibnik Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records Am J Hum Genet 88 2011 57 69
23. Y. Kochi, A. Suzuki, R. Yamada, and K. Yamamoto Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis Nat Rev Rheumatol 6 2010 290 295
24. K. Teller, L. Budhai, M. Zhang, N. Haramati, H.D. Keiser, and A. Davidson HLA-DRB1 and DQB typing of Hispanic American patients with rheumatoid arthritis: the "shared epitope" hypothesis may not apply J Rheumatol 23 1996 1363 1368
25. E.A. Perkins, D. Landis, and Z.L. Causey Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans Arthritis Rheum 64 2012 1355 1358
26. K. Lundberg, C. Bengtsson, and N. Kharlamova Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile Ann Rheum Dis 72 2013 652 658 and Skin Diseases